These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24258313)

  • 41. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
    Eggener S
    Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer.
    Sciarra A; Di Chiro C; Di Silverio F
    World J Urol; 2000 Dec; 18(6):392-400. PubMed ID: 11204257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
    Schröder FH; Collette L; de Reijke TM; Whelan P
    Br J Cancer; 2000 Jan; 82(2):283-90. PubMed ID: 10646878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
    Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ
    Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
    Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
    Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
    Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
    Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
    Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.
    Salonen AJ; Taari K; Ala-Opas M; Sankila A; Viitanen J; Lundstedt S; Tammela TL;
    Scand J Urol; 2014 Dec; 48(6):513-22. PubMed ID: 24679247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
    Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS
    J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.
    Casas F; Henríquez I; Bejar A; Maldonado X; Alvarez A; González-Sansegundo C; Boladeras A; Ferrer F; Hervás A; Herruzo I; Caro M; Rodriguez I; Ferrer C
    Clin Transl Oncol; 2017 Mar; 19(3):373-378. PubMed ID: 27770397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
    de Voogt HJ
    Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
    Nozawa M; Inagaki T; Nagao K; Nishioka T; Komura T; Esa A; Kitagawa M; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uejima S; Matsuyama H; Hara I; Uemura H
    Int J Clin Oncol; 2014 Aug; 19(4):693-701. PubMed ID: 23912936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
    Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
    Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
    Kil PJ; Goldschmidt HM; Wieggers BJ; Kariakine OB; Studer UE; Whelan P; Hetherington J; de Reijke TM; Hoekstra JW; Collette L
    Eur Urol; 2003 Jan; 43(1):31-8. PubMed ID: 12507541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.